SIGA Technologies, Inc. (SIGA)
NASDAQ: SIGA · Real-Time Price · USD
5.98
+0.05 (0.93%)
Apr 17, 2025, 4:00 PM EDT - Market closed
SIGA Technologies Revenue
In the year 2024, SIGA Technologies had annual revenue of $138.72M, down -0.86%. SIGA Technologies had revenue of $81.47M in the quarter ending December 31, 2024, a decrease of -30.06%.
Revenue (ttm)
$138.72M
Revenue Growth
-0.86%
P/S Ratio
3.08
Revenue / Employee
$3,015,638
Employees
46
Market Cap
427.91M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 138.72M | -1.20M | -0.86% |
Dec 31, 2023 | 139.92M | 29.14M | 26.31% |
Dec 31, 2022 | 110.78M | -22.89M | -17.13% |
Dec 31, 2021 | 133.67M | 8.71M | 6.97% |
Dec 31, 2020 | 124.96M | 98.22M | 367.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SIGA News
- 11 days ago - SIGA Declares Special Cash Dividend of $0.60 Per Share - GlobeNewsWire
- 12 days ago - SIGA Technologies: Asymmetric Upside, If 2025 Goes Right - Seeking Alpha
- 4 weeks ago - SIGA Appoints Retired General John M. Keane to its Board of Directors - GlobeNewsWire
- 5 weeks ago - SIGA Technologies, Inc. (SIGA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024 - GlobeNewsWire
- 6 weeks ago - SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses - GlobeNewsWire
- 4 months ago - Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced - GlobeNewsWire